Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Benzinga · 2d ago
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.